Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study.

MLA

Agarwal, Neeraj, et al. “Health-Related Quality of Life after Apalutamide Treatment in Patients with Metastatic Castration-Sensitive Prostate Cancer (TITAN): A Randomised, Placebo-Controlled, Phase 3 Study.” The Lancet. Oncology, vol. 20, no. 11, Nov. 2019, pp. 1518–30. EBSCOhost, https://doi.org/10.1016/S1470-2045(19)30620-5.

APA

Agarwal, N., McQuarrie, K., Bjartell, A., Chowdhury, S., Pereira de Santana Gomes, A. J., Chung, B. H., Özgüroğlu, M., Juárez Soto, Á., Merseburger, A. S., Uemura, H., Ye, D., Given, R., Cella, D., Basch, E., Miladinovic, B., Dearden, L., Deprince, K., Naini, V., Lopez-Gitlitz, A., & Chi, K. N. (2019). Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study. The Lancet. Oncology, 20(11), 1518–1530. https://doi.org/10.1016/S1470-2045(19)30620-5

Chicago

Agarwal, Neeraj, Kelly McQuarrie, Anders Bjartell, Simon Chowdhury, Andrea J Pereira de Santana Gomes, Byung Ha Chung, Mustafa Özgüroğlu, et al. 2019. “Health-Related Quality of Life after Apalutamide Treatment in Patients with Metastatic Castration-Sensitive Prostate Cancer (TITAN): A Randomised, Placebo-Controlled, Phase 3 Study.” The Lancet. Oncology 20 (11): 1518–30. doi:10.1016/S1470-2045(19)30620-5.